Journal of Advanced Zoology

ISSN: 0253-7214

*Volume **44** Issue S-06 **Year 2023** Page 2236:2242*

Recombinant Protein Production: Advancements And Applications

Dipti Das[1], Semanti Ghosh[2], Bidisha Ghosh[3], Subhasis Sarkar[4], Suranjana Sarkar[5*]

[1]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal700121, Email: mana.das2004@gmail.com, Ph: -7044794153

[2]Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: semantig@svu.ac.in, Ph- 9432912893

[3]Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: bidishag@svu.ac.in, Ph- 8017314552

[4]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: subhasiss@svu.ac.in, Ph- 960919374

[5]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph: 8981278415*

***Corresponding Author:** Suranjana Sarkar*

**Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph: 8981278415*

Article History

***Received:** 30/09/2023*
***Revised:** 05/10/2023*
***Accepted:**03/11/2023*

Abstract

Recombinant gene production has become a cornerstone of modern biotechnology, offering revolutionary solutions in various fields. This abstract explores the diverse applications of recombinant gene technology, highlighting its pivotal role in medicine, agriculture and industry, while also discussing the latest advancements and challenge.

Recombinant gene production involves the deliberate manipulation of genetic material to create hybrid DNA sequences with desired traits. This technology has enabled the synthesis of therapeutic proteins, vaccines and enzymes that were once scarce or inaccessible. In medicine recombinant gene expression systems have revolutionized the treatment of various diseases, ranging from insulin production for diabetes management to monoclonal antibody therapies for cancer treatment.

In agriculture, recombinant gene technology has been harnessed to develop genetically modified crops with enhanced nutritional content, resistance to pests and diseases and improve yield. These advancements hold promise for addressing global food security challenges, although they also raise concerns about ecological impact and consumer acceptance. Industrial applications of recombinant gene production encompass the production of biofuels, bioplastics and wide array of bio-based chemicals. This technology enables the cost effective production of valuable compounds through microbial fermentation or other bioprocesses, contributing to sustainable manufacturing practices.

Recent advancements in recombinant gene production include the development of novel expression systems such as synthetic biology tools that enable precise control over gene expression and metabolic pathways. Additionally, innovations like CRISPR based genome editing

CC License CC-BY-NC-SA 4.0	*have accelerated the modification of host organisms for improved recombinant protein yields and functionalities.* *Despite its transformative potential, recombinant gene production faces challenges. Ensuring the safety and regulatory compliance of genetically modified products remain a priority. Furthermore, optimising expression systems to maximize yields, scalability, and post translational modifications is ongoing endeavour.*

Introduction

The introduction of recombinant pharmaceutical proteins represents a monumental milestone in the field of biotechnology and medicine, ushering in a transformative era that has redefined the landscape of healthcare. These remarkable proteins, meticulously designed and synthesized through advanced genetic techniques, embody the convergence of scientific innovation and therapeutic potential. With their capacity to precisely target and modulate specific molecular pathways, recombinant pharmaceutical proteins have opened new frontiers in prevention and treating a wide spectrum of diseases, ranging from genetic disorders to chronic illnesses. This introduction provides a comprehensive exploration of the fascinating realm of recombinant pharmaceutical proteins, tracing their origins, elucidating their diverse and dynamic applications, and highlighting the profound and enduring impact they have had on modern healthcare. In doing so, we embark on a journey through the remarkable world of biotechnology, where the fusion of scientific discovery and medical ingenuity continues to forge groundbreaking therapies, redefine treatment paradigms, and elevate the possibilities of health and well-being for individuals and communities worldwide (Gupta *et al.,* 2016).

The benefits of employing recombinant DNA technology for protein production

Recombinant DNA technology has profoundly transformed the landscape of therapeutic protein production, introducing several notable advantages. A pivotal advancement is the significant reduction in immunogenicity achieved through the cloning and expression of human genes. This strategic approach minimizes the potential for immune responses to the produced proteins, ensuring a heightened level of compatibility during medical treatments and yielding proteins with superior specific activity. Furthermore, the technology facilitates an efficient and cost-effective production process for therapeutic proteins, guaranteeing a sustainable and economically viable supply. Another critical dimension is the heightened safety profile, with recombinant DNA technology markedly decreasing the risk of transmitting unidentified pathogens that may be present in animal and human sources. Additionally, the technology allows for precise modifications of proteins, resulting in enhancements in specificity, prolonged half-life within the body, and improved functionality. This precision in modification opens avenues for strategically tailoring proteins to address diverse medical conditions. In essence, recombinant DNA technology stands as a cornerstone in therapeutic protein production, offering a myriad of advantages that contribute to the safety, efficiency, and customization of medical treatments (Davami *et al.,* 2011; Kim *et al.,* 2018).

Procedure

Recombinant DNA technology involves genetic engineering which initiating with identification, followed by isolation and insertion target gene of into a desired vector that will be transformed into host cell which will further replicate and produce multiple copies of the host cell with the recombined gene present in it. Each steps are further described below:

DNA Extraction

DNA extraction purifies DNA by physical and chemical methods, involves cell lysis and DNA solubilisation.

- Lysis of cell can be done by using non-ionic detergents (Sodium dodecyl sulfate), Tris-cl and EDTA.
- Removal of cell debris by centrifugation. Organic solvents like phenol and chloroform are employed for DNA Denaturation. RNASE treatment removes unwanted RNA.
- The DNA is purified and Re dissolved in TA buffer ((Mital *et al.,* 2021).

Isolation of Gene of Interest

Restriction endonucleases are enzymes derived from bacteria that cleaves duplex DNA in specific targetsequences. In bacteria these enzymes are a part of restriction modification system against other exogenous

or foreign DNA particle. This enzyme cleaves specific segments of the DNA which are called as recognitionor restriction sites. Each restriction endonucleases have different restriction sites. Theseenzymes cleaves DNA in the form of blunt or sticky ended. Endonucleases works by breaking the internal phosphodiesterbonds within the DNA molecule.

Restriction digestion cuts DNA segment into smaller lengths, using restriction endonucleases. We will require a DNA from which we will isolate the GOI, a restriction enzyme, assay buffer for that particular enzyme, molecular grade water.

(a)The DNA and the enzyme are basically proteins so it should be kept in cool conditions. Until the reaction starts we have to keep it in ice.

(b)Mix the DNA and the restriction enzyme together with the buffer and the water in a tube by gentle pipetting and tapping.

(c)Incubate these tubes for 1 hour at 37 Degree Celsius.

(d)Place the tubes at room temperature for 10 min.

(e) Agarose gel electrophoresis.

DNA fragments of varying lengths are separated by Agarose gel electrophoresis. Upon separation, the fragments of various sizes are visible under UV light. The lengths of respective fragments can be determined from the DNA ladder.

Isolation of Vector

Vector is a molecule of DNA, employed as a carrier of a particular gene of interest, GOI. It introduces the GOI into a targeted host cell. Yeast cells, viruses, and plasmids are commonly used vectors. Plasmids vectors are much easier to manipulate than the virus.Plasmids can defined as Extra chromosomal covalently closed circular DNA. Bacterial cells contain an extra chromosome other than the nucleoid in the form of plasmids. A plasmid with antibiotic resistant gene is chosen for this procedure. They can be isolated from the bacterial cell by the process known as alkaline lysis.

- Bacterial cell lysis using sodium dodecyl sulfate (SDS) and sodium hydroxide solution, aiming to denature chromosomes and plasmid DNA.
- Potassium acetate is used reanneal plasmid DNA, and solubilise.
- Potassium and SDS complexes with chromosomal DNA and proteins, which is then removed by centrifugation.
- The plasmid is collected fom supernatant using ethanol (Ehrt, 2003). After the extraction of plasmid DNA,it should be restriction digested to form a specific cut in the circular DNA where the gene of interest will be inserted.

Ligation

It is a procedure where two or more DNA fragments is joined via a ligase catalysed reaction. The enzyme DNA Ligase which is used in this process are found in all living cells. DNA ligase from bacteria *E.coli* and T4 DNA ligase from T4 phage are the two main tools that is used in genetic engineering. (Gaastra W et al, 1985) DNA ligases ligates 5` Phosphate and 3` OH polynucleotides end by making a phosphodiester bond between the two fragments. The formation of recombinant plasmids result from ligation between one end of the linearized vector and one end of the gene of interest with the help of enzyme DNA ligase.

Transformation

The uptake of DNA materials through the cell membrane in bacterial and non- bacterial cells is known as transformation. In bacterial cells, we can transform the exogenous DNA by Artificial transformation and transfection process. In non- bacterial cells, we can transform the exogenous DNA by electroporation, liposome mediated transfer, protoplast delivery, microinjection. Competent cells and the ligated DNA is then allowed to incubate at 42 Degree Celsius for 45 seconds. It is again put into ice. SOC media is added and the cells are again incubated at 37 Degree Celsius for 30 min with agitation. After these step, the recombinant cells multiplies for the production of various enzymes, hormones, vaccines, genetically modified organisms and crops, new drug development (Adrio *et al.*, 2010).

Protein Glycolystion

Glycosylation, a crucial protein modification, takes place in the endoplasmic reticulum (ER) and Golgi complex. N-linked glycosylation starts in the ER and continues in the Golgi, while O-linked glycosylation occurs exclusively in the Golgi. The process begins with oligosaccharide binding to dolichol phosphate in the ER. Enzymes on the ER's luminal side facilitate the transfer to a specific asparagine residue on the polypeptide

chain. Glycosylated proteins then travel to the Golgi for additional carbohydrate modifications. This complex journey ensures proper glycoprotein maturation, vital for their functionality, before being targeted and transported to cellular destinations (Gupta *et al*., 2016).

Protein Folding

The importance of protein folding in the production of recombinant proteins is extensive and varied. Protein folding, a sophisticated and tightly regulated process, is pivotal in determining the three-dimensional structure of a polypeptide chain. This structural arrangement is crucial for the proper biological functioning, stability, and solubility of proteins. Ensuring correct protein folding has implications for functional activity, especially in proteins like enzymes and receptors that rely on specific folded configurations for their intended roles. Additionally, proper folding contributes to the stability of recombinant proteins, reducing the likelihood of denaturation or aggregation that could compromise their efficacy over time. Solubility is also positively influenced by correct folding, facilitating the purification process. Furthermore, misfolded proteins are more susceptible to eliciting immunogenic responses, potentially jeopardizing the safety and efficacy of therapeutic recombinant proteins. Efficient secretion, prevention of aggregation, and preservation of biological activity all hinge on the precise folding of proteins. In the domain of therapeutic proteins, such as monoclonal antibodies or hormones, the clinical relevance of correct folding is paramount, directly influencing drug efficacy and safety. Consequently, researchers and biotechnologists engaged in recombinant protein production prioritize optimizing conditions to facilitate and ensure proper protein folding throughout the production and purification processes (Gupta *et al*., 2016).

Production of Recombinant Protein Various Hosts

The utilization of diverse host cells for the production of recombinant proteins offers numerous advantages but is also accompanied by specific limitations that require careful consideration during the selection process.

Bacterial cells, exemplified by *Escherichia coli*, provide rapid growth, yet their capacity for complex post-translational modifications, such as glycosylation, is limited. Challenges related to protein folding and potential endotoxin contamination further characterize this system. Fungal cells, particularly yeast (*Saccharomyces cerevisiae*), exhibit distinct glycosylation patterns and may encounter issues of hyperglycosylation, impacting protein functionality. Additionally, limitations in the secretion of certain complex proteins pose scalability challenges.

Plant cells, while offering a unique system, present differences in glycosylation patterns and may demonstrate low expression levels for specific proteins, necessitating large amounts of plant material and extended processing times. Mammalian cells, notably Chinese hamster ovary (CHO) cells, facilitate proper post-translational modifications but come with higher production costs, scale-up challenges, and a risk of contamination (Kamionka *et al.*, 2011).

Case Study

Ensuring the safety of therapeutic products developed through recombinant technology, especially those from mammalian cells, is paramount. The cultivation of mammalian cells in media containing serum raises concerns about potential contamination by infectious agents, including viruses like HIV, HBV, HCV, and emerging pathogens. Historical incidents of contamination with blood-derived coagulation factors underscore the need to address pathogen transmission risks urgently. A significant breakthrough was achieved with recombinant factor VIII, exemplified by Advate. Produced in Chinese hamster ovary cells in serum-free and protein-free media, Advate eliminates the risk of bloodborne pathogen transmission, enhancing safety in therapeutic applications. The threat of prions, resilient infectious proteins linked to severe diseases, led to the withdrawal of cadaveric pituitary-derived hormones. Recombinant alternatives, such as growth hormone and gonadotropins produced using recombinant technologies, have replaced these, ensuring a safer therapeutic landscape. This strategic shift underscores the crucial role of recombinant technologies in minimizing the risk of infectious agent transmission in clinical applications (Dhillon, 2012).

Biopharmaceuticals

Biopharmaceuticals, also referred to as biologics, represent therapeutic products derived from living organisms or their components, fundamentally transforming the landscape of medical treatments. These innovative products have become pivotal in addressing a wide array of diseases. Notable categories of biopharmaceuticals include (Kesik-Brodacka *et al.*, 2018):

1. Monoclonal Antibodies (mAbs):
- Utilized in the treatment of cancer, autoimmune disorders, and inflammatory conditions. Exemplars include Rituximab, Trastuzumab, and Adalimumab.

2. Vaccines:
- Crucial for preventing infectious diseases.
- Prominent examples encompass the Human papillomavirus (HPV) vaccine, Hepatitis B vaccine, and mRNA-based COVID-19 vaccines.

3. Recombinant Proteins:
- Engineered proteins serving to replace or augment natural proteins in the body.
- Illustrations involve Insulin, Erythropoietin (EPO), and Growth Hormone.

4. Antibody-Drug Conjugates (ADCs):
- Combine the specificity of antibodies with the cytotoxicity of drugs.
- Noteworthy instance: Brentuximab vedotin.

5. Enzyme Replacement Therapies:
- Employed for rare genetic disorders characterized by specific enzyme deficiencies.
- Epitomized by Imiglucerase for Gaucher's disease.

6. Cytokines:
- Regulators of immune responses extensively used in cancer immunotherapy.
- Examples encompass Interferons and Interleukins.

7. Gene Therapies:
- Introduce genetic material into patient cells to treat or prevent diseases.
- Illustrative instances include Luxturna and Zolgensma for inherited retinal dystrophy and spinal muscular atrophy.

Application of Recombinant Proteins

Recombinant proteins have a multitude of applications that span various disciplines. In the realm of biomedical research, these proteins are indispensable tools for investigating cellular processes, deciphering intricate signaling pathways, and elucidating the mechanisms underlying diseases. Researchers employ recombinant proteins as invaluable probes, markers, and experimental controls, facilitating a deeper understanding of biology and pathophysiology. In the domain of drug development, recombinant proteins play a pivotal role by serving as primary targets for drug screening, enabling the discovery of potential therapeutic compounds. Moreover, recombinant proteins themselves are employed as biopharmaceuticals, with monoclonal antibodies and therapeutic enzymes being prime examples. This versatility and precision in addressing specific biological processes underscore the significance of recombinant proteins in advancing scientific knowledge and driving innovation in medicine and beyond (Gifre *et al.*, 2017; Swiech et., 2011**)**.

Challenges

The realm of biopharmaceuticals is confronted with a multitude of challenges encompassing scientific, technical, regulatory, and economic facets. The intricate nature of manufacturing processes, often involving living cells, introduces complexity, impacting both the cost and accessibility of biopharmaceuticals. Elevated production expenses, attributed to specialized equipment, stringent quality control measures, and extensive testing, raise concerns regarding the affordability and widespread availability of these therapies. Regulatory approval presents a formidable hurdle, necessitating comprehensive data on safety, efficacy, and consistency. The issue of immunogenicity, or the potential for immune reactions, poses a substantial challenge, influencing the sustained efficacy and safety of biopharmaceuticals. Ensuring accurate post-translational modifications, establishing stable cell lines, and addressing supply chain logistics add further layers to the multifaceted challenges faced by the field. The advent of biosimilars introduces considerations regarding interchangeability and the maintenance of comparable efficacy and safety profiles. Achieving global market access and ensuring patient affordability, particularly in resource-limited regions, remains an ongoing challenge, emphasizing the

imperative for collaborative efforts to navigate and overcome the intricate landscape of biopharmaceutical development.

Future Prospect

The future of producing proteins through recombinant DNA technology holds immense promise, with several exciting avenues for advancement. One key area of focus is enhancing protein expression, with ongoing research dedicated to optimizing production efficiency and increasing yields. The precise control of post-translational modifications (PTMs) is another forefront, aiming to develop systems that produce proteins with fully humanized PTMs, reducing the risk of immunogenic reactions. Customization is set to play a pivotal role, as synthetic biology and gene editing technologies advance, allowing for the creation of tailor-made proteins with specific functions. Innovative host systems, such as engineered microbes and cell-free platforms, offer the potential for improved scalability and cost-effectiveness. Additionally, the integration of artificial intelligence (AI) and machine learning will streamline protein design and production processes. Cell-free protein synthesis is gaining prominence, potentially revolutionizing protein production by eliminating the need for living cells. As these developments unfold, the diversity of therapeutic proteins is expected to expand, addressing a wider spectrum of medical conditions. Moreover, global accessibility efforts aim to make these technologies available in resource-limited regions, fostering the development of affordable treatments and vaccines and advancing healthcare on a global scale. There are lot of advantages that can be gained by using recombinant DNA technology as it encompasses ambitious future holds. Tis approach helps to reduce genetic diseases in agriculture fields in order to produce better and improved crops. It also has advance strategies in cancer treatment, genetic diseases. This technology is also involved in forensic science.

Conclusion

In conclusion, the field of biopharmaceuticals presents a dynamic landscape characterized by groundbreaking innovations and transformative therapies. However, the journey is not without its challenges. The intricacies of manufacturing processes, coupled with the high production costs, underscore the need for continued advancements in technology and manufacturing practices to enhance accessibility. Regulatory complexities demand a meticulous approach to demonstrate the safety, efficacy, and consistency of biopharmaceuticals. The persistent challenge of immunogenicity necessitates ongoing research to ensure the sustained effectiveness and safety of these therapies over time. As the industry grapples with issues related to post-translational modifications, stable cell lines, and supply chain logistics, collaboration among stakeholders becomes paramount. The emergence of biosimilars adds a layer of complexity, urging careful considerations for interchangeability and maintaining comparable profiles. Despite these challenges, the potential for global market access and patient affordability underscores the importance of collaborative efforts to overcome barriers and pave the way for a future where biopharmaceuticals continue to revolutionize healthcare. Through collective innovation and strategic collaboration, the field is poised to address these challenges, further advancing the frontiers of biopharmaceutical development for the benefit of patients worldwide.

Acknowledgements

The authors express their sincere gratitude to the higher authorities of Swami Vivekananda University and the School of Life Sciences for their unwavering support and for fostering an environment of excellence.

Author Contribution

Data collection and analysis for this project were skillfully carried out by a team comprising Dipti Das. The conceptualization, design, and comprehensive refinement of the article were led by Suranjana Sarkar, Dr. Semanti Ghosh, Bidisha Ghosh, and Dr. Subhasis Sarkar.

Conflict of Interest

The authors declare that there are no conflicts of interest.

Declaration

The authors affirm the accuracy and truthfulness of the information presented in this document to the best of

their knowledge.

Reference

1. Adrio, J. L., & Demain, A. L. (2010). Recombinant organisms for production of industrial products. *Bioengineered bugs*, *1*(2), 116–131. https://doi.org/10.4161/bbug.1.2.10484
2. Davami, F., Barkhordari, F., Alebouyeh, M., Adeli, A., & Mahboudi, F. (2011). Combined TGE-SGE expression of novel PAI-1-resistant t-PA in CHO DG44 cells using orbitally shaking disposable bioreactors. *Journal of microbiology and biotechnology*, *21*(12), 1299–1305. https://doi.org/10.4014/jmb.1106.05060
3. Gifre, L., Arís, A., Bach, À., & Garcia-Fruitós, E. (2017). Trends in recombinant protein use in animal production. *Microbial cell factories*, *16*(1), 40. https://doi.org/10.1186/s12934-017-0654-4
4. Gupta, V., Sengupta, M., Prakash, J., & Tripathy, B. C. (2016). Production of Recombinant Pharmaceutical Proteins. *Basic and Applied Aspects of Biotechnology*, 77–101. https://doi.org/10.1007/978-981-10-0875-7_4
5. Kamionka M. (2011). Engineering of therapeutic proteins production in Escherichia coli. *Current pharmaceutical biotechnology*, *12*(2), 268–274. https://doi.org/10.2174/138920111794295693
6. Kim, K. H., Jia, X., Jia, B., & Jeon, C. O. (2018). Identification and Characterization of l-Malate Dehydrogenases and the l-Lactate-Biosynthetic Pathway in Leuconostoc mesenteroides ATCC 8293. *Journal of agricultural and food chemistry*, *66*(30), 8086–8093. https://doi.org/10.1021/acs.jafc.8b02649
7. Mital, S., Christie, G., & Dikicioglu, D. (2021). Recombinant expression of insoluble enzymes in Escherichia coli: a systematic review of experimental design and its manufacturing implications. *Microbial cell factories*, *20*(1), 208. https://doi.org/10.1186/s12934-021-01698-w
8. Swiech, K., Kamen, A., Ansorge, S., Durocher, Y., Picanço-Castro, V., Russo-Carbolante, E. M., Neto, M. S., & Covas, D. T. (2011). Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII. *BMC biotechnology*, *11*, 114. https://doi.org/10.1186/1472-6750-11-114
9. Kesik-Brodacka M. (2018). Progress in biopharmaceutical development. *Biotechnology and applied biochemistry*, *65*(3), 306–322. https://doi.org/10.1002/bab.1617
10. Dhillon S. (2012). Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A. *Drugs*, *72*(7), 987–1007. https://doi.org/10.2165/11207480-000000000-00000